Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CURB-65

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: CURB-65. Displaying page 1 of 1.
    EudraCT Number: 2012-003067-22 Sponsor Protocol Number: PRISTINE Start Date*: 2012-11-19
    Sponsor Name:LUMC
    Full Title: Pneumonia treated with rifampicine attenuates inflammation
    Medical condition: Community acquired pneumonia CURB-65 class >1
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001357-52 Sponsor Protocol Number: EnCovid-hidroxiCLOROQUINA Start Date*: 2020-05-13
    Sponsor Name:IDIVAL
    Full Title: Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in...
    Medical condition: Quimioprophylaxis of SARS-CoV-2 infection with hydroxyloquine (HCQ) in patients diagnosed with an immunomediated inflammatory disease who are following a treatment with biological agents and / or J...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021982 Inflammatory disorders following infection HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002683-32 Sponsor Protocol Number: DUR001-305 Start Date*: 2015-03-30
    Sponsor Name:Durata Therapeutics International B.V.
    Full Title: A Phase 3, double-blinded, randomized, comparator trial of the safety and efficacy of a single dose of dalbavancin to twice daily linezolid for the treatment of community acquired bacterial pneumonia
    Medical condition: Community acquired bacterial pneumonia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002032-69 Sponsor Protocol Number: COVITOZ-01 Start Date*: 2020-05-04
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
    Full Title: Single-center, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19
    Medical condition: Non-severe pneumonia caused by COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002119-23 Sponsor Protocol Number: IEO1253 Start Date*: 2020-11-16
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: COVitaminD Trial: prevention of complications from COVID-19 in cancer patients under active treatment
    Medical condition: Oncological patients in active oncological treatment diagnosed with Covid-19
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10010029 Colorectal cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001735-66 Sponsor Protocol Number: NXL103/2001 Start Date*: 2007-10-01
    Sponsor Name:Novexel S. A.
    Full Title: A double blind, multicentre, multinational, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL103 (500 mg twice daily) versus NXL...
    Medical condition: Community-Acquired Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001290-74 Sponsor Protocol Number: SARICOVID Start Date*: 2020-04-11
    Sponsor Name:Consorci Parc de Salut Mar (PSMAR)
    Full Title: Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care
    Medical condition: Patients with confirmed COVID-19 infection and criteria for mild-moderate pneumonia (CURB-65 ≤1 i SatO2 ≥90%, MEWS score less than 3) and IL6 values of 20 pg / ml, will be randomly assigned to a sa...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035737 Pneumonia viral PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003026-14 Sponsor Protocol Number: ML-3341-306 Start Date*: 2016-02-04
    Sponsor Name:Melinta Therapeutics, Inc.
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTE...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) LV (Completed) BG (Completed) DE (Completed) SI (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 16:18:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA